Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07934264
EARLY_PHASE1

[18F]ZDG2 First-in-Human PET Imaging in PAH

Sponsor: The Methodist Hospital Research Institute

View on ClinicalTrials.gov

Summary

The goal of this study is to find out whether \[18F\]ZDG2 can detect early blood vessel changes in people with pulmonary arterial hypertension (PAH). The study will help answer this question: Can a positron emission tomography (PET) scan using \[18F\]ZDG2 help identify PAH? Participants will: * Receive one or two doses of the study tracer \[18F\]ZDG2 and have a PET/CT scan after each dose * Provide blood and urine samples * Tell the study team about any side effects or symptoms you experience

Official title: First-in-Human PET Imaging of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension Using [18F]ZDG2: Safety, Biodistribution, Dosimetry and Pharmacokinetics

Key Details

Gender

All

Age Range

21 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2026-11-14

Completion Date

2028-10-31

Last Updated

2026-11-18

Healthy Volunteers

Yes

Interventions

DRUG

[18F]ZDG2- Single Dose

\[18F\]ZDG2 will be administered as an intravenous injection on the day of imaging. Participants in the reproducibility cohort will receive an additional dose and imaging session one to weeks after the first. Heathy volunteers and PAH patients not in the reproducibility cohort will receive only one dose and imaging session.

Locations (1)

Houston Methodist Research Institute

Houston, Texas, United States